Lawrence Einhorn
劳伦斯·爱因霍恩
MD
Distinguished Professor of Medicine, Lance Armstrong Foundation Professor医学杰出教授、兰斯·阿姆斯特朗基金会讲席教授
👥Biography 个人简介
Lawrence Einhorn is the pioneer who developed BEP chemotherapy (bleomycin, etoposide, cisplatin), transforming testicular cancer from a fatal disease to one with over 95% cure rates. His landmark 1977 study is among the most consequential in oncology history, saving hundreds of thousands of lives.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BEP Chemotherapy Regimen
Developed and validated the BEP (bleomycin, etoposide, cisplatin) chemotherapy regimen in 1977, achieving cure rates above 95% in disseminated testicular cancer and establishing a paradigm for curative chemotherapy.
Salvage Therapy in Testicular Cancer
Pioneered high-dose chemotherapy with autologous stem cell rescue as salvage therapy for relapsed germ cell tumors, providing curative options for patients failing first-line treatment.
Representative Works 代表性著作
Combination Chemotherapy in Disseminated Testicular Cancer
Annals of Internal Medicine (1977)
Landmark study establishing cisplatin-based BEP regimen achieving unprecedented cure rates in metastatic testicular cancer.
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ Cell Tumors
New England Journal of Medicine (2007)
Established high-dose salvage chemotherapy as curative option for platinum-refractory testicular cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 劳伦斯·爱因霍恩 的研究动态
Follow Lawrence Einhorn's research updates
留下邮箱，当我们发布与 Lawrence Einhorn（Indiana University Melvin and Bren Simon Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment